📉 Cohance Lifesciences Hits Multi-Year Low — What’s Driving the Sharp Fall?

Shares of Cohance Lifesciences (NSE:

), formerly known as Suven Lifesciences, have plunged to ₹311, marking a 52-week low and the lowest level since December 2020. The stock has corrected over 75% from its 52-week high of ₹1,328. Recent Performance: • 1 Week: –7% • 1 Month: –30% • YTD: –40% • 1 Year: –71% The sharp decline follows weak Q3 FY26 results, with nearly a 60% drop in earnings alongside lower revenue. Key concerns include ongoing USFDA observations at its Hyderabad API facility, raising compliance and export uncertainty. Leadership instability added pressure after the Managing Director’s resignation in October 2025 triggered a double-digit fall. With earnings stress, regulatory overhang, and sentiment damage, the stock remains under bearish control. What’s your view — potential turnaround opportunity or continuation of the downtrend? 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered advisor before making any investment decisions.